Cytori Therapeutics Inc Stock Nasdaq
Equities
US23283K2042
Biotechnology & Medical Research
Sales 2024 * | 6.93M 9.46M | Sales 2025 * | 2.87M 3.91M | Capitalization | 9.32M 12.73M |
---|---|---|---|---|---|
Net income 2024 * | -17M -23.21M | Net income 2025 * | -31M -42.33M | EV / Sales 2024 * | 1.35 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.25 x |
P/E ratio 2024 * |
-1
x | P/E ratio 2025 * |
-0.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.82% |
Latest transcript on Cytori Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 61 | 02-09-30 |
Andrew Sims
DFI | Director of Finance/CFO | 51 | 20-02-05 |
Pius Maliakal
CTO | Chief Tech/Sci/R&D Officer | - | 23-07-26 |
Members of the board | Title | Age | Since |
---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 61 | 02-09-30 |
Richard Hawkins
CHM | Chairman | 75 | 07-11-30 |
Robert Lenk
BRD | Director/Board Member | 75 | 20-02-29 |
1st Jan change | Capi. | |
---|---|---|
+42.62% | 54.04B | |
+43.57% | 41.96B | |
-1.45% | 41.92B | |
-7.59% | 28.35B | |
+11.35% | 26.35B | |
-22.21% | 19B | |
+7.47% | 13B | |
+28.43% | 12.28B | |
+25.59% | 12.19B |